<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792635</url>
  </required_header>
  <id_info>
    <org_study_id>B1731003</org_study_id>
    <nct_id>NCT01792635</nct_id>
  </id_info>
  <brief_title>A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 6-week Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral Pf-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of
      oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated prematurely on 16 May 2014 due to a safety concern.
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Infusion Rates (GIR) in Part A</measure>
    <time_frame>1 day</time_frame>
    <description>GIR obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. Assessment of whole body insulin sensitivity was performed during the steady states of the low insulin infusion rate (ie, Step 1) and during the steady state of the high insulin infusion rate (ie, Step 2). These indices were called GIR1 and GIR2, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endogenous Gucose Production (EGP) in Part A</measure>
    <time_frame>1 day</time_frame>
    <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2). Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. EGP was measured under basal conditions; then during the low dose insulin infusion EGP was partially suppressed (hepatic insulin sensitivity), while during the high dose insulin infusion, EGP was almost completely suppressed and peripheral glucose uptake was maximally stimulated (peripheral insulin sensitivity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>[6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A</measure>
    <time_frame>1 day</time_frame>
    <description>[6,6-2H2] PGE was the molar fraction of labeled glucose measured in plasma. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Appearance of Glucose (Ra) in Part A</measure>
    <time_frame>1 day</time_frame>
    <description>Rate of appearance of glucose (Ra) in fasting state and during insulin infusions (Step 1 and Step 2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole-body Glucose Uptake in Part A</measure>
    <time_frame>1 day</time_frame>
    <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole-body Glucose Uptake in Part B in Placebo Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole-body Glucose Uptake in Part B in PF-05175157 200 mg BID Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs) in Part B</measure>
    <time_frame>Baseline to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
    <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Test Abnormalities in Part B</measure>
    <time_frame>Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
    <description>Number of participants with laboratory test abnormalities without regard to baseline abnormality. The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatine phosphokinase); urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy); others (follicle stimulating hormone [FSH], urine drug screen, lipid profile and very-low-density lipoproteins [VLDL], hemoglobin A1c [HbA1c], C-peptide, thyroid-stimulating hormone [TSH], Hepatitis B and C, human immunodeficiency virus [HIV], triglycerides, urine creatinine).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria in Part B</measure>
    <time_frame>Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
    <description>Criteria for potentially clinical important (PCI) change in vital signs included: sitting systolic blood pressure (SBP) of less than (&lt;) 90 millimeters of mercury (mm Hg) or change in sitting SBP of greater or equal to (&gt;=)30 mm Hg, sitting diastolic blood pressure (DBP) of &lt;50 mm Hg or change in sitting DBP of &gt;=20 mm Hg, sitting pulse rate of &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B</measure>
    <time_frame>Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
    <description>Criteria for PCI changes in ECG (12-lead) were defined as: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval) &gt;=300 milliseconds (msec) and increase of &gt;=25% from baseline when baseline &gt;200 msec or increase of &gt;=50% when baseline less than or equal to (&lt;=) 200 msec; the time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS interval) &gt;=140 msec and increase of &gt;=50% from baseline; the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT), corrected for heart rate (QTc) using the Fridericia formula (QTcF) of 450 to &lt; 480 msec and &gt;=480 msec, or an increase from baseline of 30 to &lt;60 msec or &gt;=60 msec.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GIR in Part B in Placebo Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GIR in Part B in PF-05175157 200 mg BID Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGP in Part B in Placebo Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGP in Part B in PF-05175157 200 mg BID Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ra in Part B in Placebo Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>Ra in fasting state and during insulin infusions (Step 1 and Step 2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ra in Part B in PF-05175157 200 mg BID Group</measure>
    <time_frame>6 weeks</time_frame>
    <description>Ra in fasting state and during insulin infusions (Step 1 and Step 2).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Part A (Pilot Study)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>PF-05175157 will be administered at 200 mg twice a day for 43 days.</description>
    <arm_group_label>Monotherapy (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.</description>
    <arm_group_label>Monotherapy (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have been diagnosed with type 2 diabetes mellitus by a medical
             professional according to the American Diabetes Association guidelines.

          -  Hemoglobin A1c of ≥7 and ≤10.0% in subjects who are metformin-naive or have not taken
             metformin for 2 months or Hemoglobin A1c of ≥6.5 and ≤9.5% in subjects who are
             metformin-naïve and are taking SU or DPP-IVi which is washed off or taking metformin
             and are willing to discontinue metformin in a 8-week washout period.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine (other
             than T2DM and hypothyroidism), gastrointestinal, cardiovascular, pulmonary, hepatic,
             psychiatric or neurologic disease.

          -  A waist circumference which makes fitting imto the bore of the MR scanner impossible.

        Subjects with history of dry eye, known ocular or systemic disease that affect the sclera
        or cornea.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731003&amp;StudyName=A%206-Week%20Study%20Of%20PF-05175157%20In%20Type%202%20Diabetes%20Mellitus</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <results_first_submitted>January 11, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2017</results_first_posted>
  <last_update_submitted>December 22, 2016</last_update_submitted>
  <last_update_submitted_qc>December 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety &amp; Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants in Part A</title>
          <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Part B</title>
          <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>PF-05175157 200 mg Twice a Day - Part B</title>
          <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants in Part A</title>
          <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Part B</title>
          <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>PF-05175157 200 mg Twice a Day - Part B</title>
          <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="9.5"/>
                    <measurement group_id="B2" value="49.3" spread="9.2"/>
                    <measurement group_id="B3" value="55.1" spread="4.6"/>
                    <measurement group_id="B4" value="51.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Infusion Rates (GIR) in Part A</title>
        <description>GIR obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. Assessment of whole body insulin sensitivity was performed during the steady states of the low insulin infusion rate (ie, Step 1) and during the steady state of the high insulin infusion rate (ie, Step 2). These indices were called GIR1 and GIR2, respectively.</description>
        <time_frame>1 day</time_frame>
        <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Part A</title>
            <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Infusion Rates (GIR) in Part A</title>
          <description>GIR obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. Assessment of whole body insulin sensitivity was performed during the steady states of the low insulin infusion rate (ie, Step 1) and during the steady state of the high insulin infusion rate (ie, Step 2). These indices were called GIR1 and GIR2, respectively.</description>
          <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp</population>
          <units>mg/min</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clamp 1 GIR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191" lower_limit="153" upper_limit="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 1 GIR2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780" lower_limit="580" upper_limit="980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 2 GIR1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" lower_limit="132" upper_limit="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Endogenous Gucose Production (EGP) in Part A</title>
        <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2). Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. EGP was measured under basal conditions; then during the low dose insulin infusion EGP was partially suppressed (hepatic insulin sensitivity), while during the high dose insulin infusion, EGP was almost completely suppressed and peripheral glucose uptake was maximally stimulated (peripheral insulin sensitivity).</description>
        <time_frame>1 day</time_frame>
        <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Part A</title>
            <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Endogenous Gucose Production (EGP) in Part A</title>
          <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2). Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity. EGP was measured under basal conditions; then during the low dose insulin infusion EGP was partially suppressed (hepatic insulin sensitivity), while during the high dose insulin infusion, EGP was almost completely suppressed and peripheral glucose uptake was maximally stimulated (peripheral insulin sensitivity).</description>
          <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp</population>
          <units>mg/kilogram (kg) body weight (BW)/min</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clamp 1 EGP0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" lower_limit="1.48" upper_limit="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 1 EGP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.51" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 1 EGP2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.02" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 2 EGP0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" lower_limit="1.59" upper_limit="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 2 EGP1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="0.71" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>[6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A</title>
        <description>[6,6-2H2] PGE was the molar fraction of labeled glucose measured in plasma. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity.</description>
        <time_frame>1 day</time_frame>
        <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Part A</title>
            <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
          </group>
        </group_list>
        <measure>
          <title>[6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A</title>
          <description>[6,6-2H2] PGE was the molar fraction of labeled glucose measured in plasma. Whole-body insulin sensitivity was assessed with the euglycemic hyperinsulinemic clamp procedure; the use of 2 stepped insulin infusions and labeled glucose allowed the differentiation between hepatic and peripheral insulin sensitivity.</description>
          <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp</population>
          <units>percentage enrichment of plasma glucose</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clamp 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="2.94" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" lower_limit="2.88" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Appearance of Glucose (Ra) in Part A</title>
        <description>Rate of appearance of glucose (Ra) in fasting state and during insulin infusions (Step 1 and Step 2).</description>
        <time_frame>1 day</time_frame>
        <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Part A</title>
            <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Appearance of Glucose (Ra) in Part A</title>
          <description>Rate of appearance of glucose (Ra) in fasting state and during insulin infusions (Step 1 and Step 2).</description>
          <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp.</population>
          <units>mg/kg BW/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clamp 1 Step 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.575" lower_limit="2.74" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 1 Step 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.829" lower_limit="9.90" upper_limit="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clamp 2 Step 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.859" lower_limit="2.24" upper_limit="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Whole-body Glucose Uptake in Part A</title>
        <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
        <time_frame>1 day</time_frame>
        <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants in Part A</title>
            <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole-body Glucose Uptake in Part A</title>
          <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
          <population>All participants randomized and who had at least one euglycemic hyperinsulinemic clamp.</population>
          <units>mg/kg BW/min</units>
          <param>Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.829" lower_limit="9.90" upper_limit="19.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Whole-body Glucose Uptake in Part B in Placebo Group</title>
        <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole-body Glucose Uptake in Part B in Placebo Group</title>
          <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/kg BW/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Step 2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.245" lower_limit="4.18" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.325" lower_limit="6.26" upper_limit="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.793" lower_limit="2.72" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.835" lower_limit="6.56" upper_limit="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.400" lower_limit="3.97" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.940" lower_limit="3.86" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.553" lower_limit="4.37" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.225" lower_limit="4.16" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Whole-body Glucose Uptake in Part B in PF-05175157 200 mg BID Group</title>
        <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole-body Glucose Uptake in Part B in PF-05175157 200 mg BID Group</title>
          <description>Whole-body glucose uptake (Rate of glucose disappearance, Rd) during the Step 2 Clamp</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/kg BW/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Step 2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.775" lower_limit="3.70" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.033" lower_limit="8.95" upper_limit="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.903" lower_limit="8.33" upper_limit="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.310" lower_limit="11.13" upper_limit="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.133" lower_limit="3.98" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.763" lower_limit="5.98" upper_limit="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.243" lower_limit="8.06" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.180" lower_limit="7.03" upper_limit="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.113" lower_limit="9.80" upper_limit="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.205" lower_limit="6.16" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs) in Part B</title>
        <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Baseline to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
        <population>All participants who were admitted to the clinical research unit (CRU) on Day -5</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs) in Part B</title>
          <description>An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>All participants who were admitted to the clinical research unit (CRU) on Day -5</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants w ith AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants w ith SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Laboratory Test Abnormalities in Part B</title>
        <description>Number of participants with laboratory test abnormalities without regard to baseline abnormality. The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatine phosphokinase); urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy); others (follicle stimulating hormone [FSH], urine drug screen, lipid profile and very-low-density lipoproteins [VLDL], hemoglobin A1c [HbA1c], C-peptide, thyroid-stimulating hormone [TSH], Hepatitis B and C, human immunodeficiency virus [HIV], triglycerides, urine creatinine).</description>
        <time_frame>Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
        <population>All participants who were admitted to the Clinical Research Unit (CRU) on Day -5</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Test Abnormalities in Part B</title>
          <description>Number of participants with laboratory test abnormalities without regard to baseline abnormality. The following laboratory parameters were analyzed: hematology (hemoglobin, hematocrit, red blood cell [RBC] count, platelet count, white blood cell [WBC] count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen [BUN], creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, and creatine phosphokinase); urinalysis (pH, glucose, protein, blood, ketones, nitrites, leukocyte esterase, and microscopy); others (follicle stimulating hormone [FSH], urine drug screen, lipid profile and very-low-density lipoproteins [VLDL], hemoglobin A1c [HbA1c], C-peptide, thyroid-stimulating hormone [TSH], Hepatitis B and C, human immunodeficiency virus [HIV], triglycerides, urine creatinine).</description>
          <population>All participants who were admitted to the Clinical Research Unit (CRU) on Day -5</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria in Part B</title>
        <description>Criteria for potentially clinical important (PCI) change in vital signs included: sitting systolic blood pressure (SBP) of less than (&lt;) 90 millimeters of mercury (mm Hg) or change in sitting SBP of greater or equal to (&gt;=)30 mm Hg, sitting diastolic blood pressure (DBP) of &lt;50 mm Hg or change in sitting DBP of &gt;=20 mm Hg, sitting pulse rate of &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
        <time_frame>Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
        <population>All participants who were admitted to the CRU on Day -5</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline and Absolute Values in Vital Signs Meeting Categorical Summarization Criteria in Part B</title>
          <description>Criteria for potentially clinical important (PCI) change in vital signs included: sitting systolic blood pressure (SBP) of less than (&lt;) 90 millimeters of mercury (mm Hg) or change in sitting SBP of greater or equal to (&gt;=)30 mm Hg, sitting diastolic blood pressure (DBP) of &lt;50 mm Hg or change in sitting DBP of &gt;=20 mm Hg, sitting pulse rate of &lt;40 or greater than (&gt;) 120 beats per minute (bpm).</description>
          <population>All participants who were admitted to the CRU on Day -5</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP &lt;90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP &lt;50 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate &lt;40 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate &gt;120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP maximum increase from baseline &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP maximum increase from baseline &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP maximum decrease from baseline &gt;=30 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP maximum decrease from baseline &gt;=20 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B</title>
        <description>Criteria for PCI changes in ECG (12-lead) were defined as: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval) &gt;=300 milliseconds (msec) and increase of &gt;=25% from baseline when baseline &gt;200 msec or increase of &gt;=50% when baseline less than or equal to (&lt;=) 200 msec; the time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS interval) &gt;=140 msec and increase of &gt;=50% from baseline; the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT), corrected for heart rate (QTc) using the Fridericia formula (QTcF) of 450 to &lt; 480 msec and &gt;=480 msec, or an increase from baseline of 30 to &lt;60 msec or &gt;=60 msec.</description>
        <time_frame>Screening up to follow-up (up to approximately 10 to 14 days after the last study drug administration)</time_frame>
        <population>All participants who were admitted to the CRU on Day -5.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline and Absolute Values in Electrocardiogram (ECG) Meeting Categorical Summarisation Criteria in Part B</title>
          <description>Criteria for PCI changes in ECG (12-lead) were defined as: the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval) &gt;=300 milliseconds (msec) and increase of &gt;=25% from baseline when baseline &gt;200 msec or increase of &gt;=50% when baseline less than or equal to (&lt;=) 200 msec; the time from the beginning of the electrocardiogram Q wave to the end of the S wave corresponding to ventricular depolarization (QRS interval) &gt;=140 msec and increase of &gt;=50% from baseline; the time corresponding to the beginning of depolarization to repolarization of the ventricles (QT), corrected for heart rate (QTc) using the Fridericia formula (QTcF) of 450 to &lt; 480 msec and &gt;=480 msec, or an increase from baseline of 30 to &lt;60 msec or &gt;=60 msec.</description>
          <population>All participants who were admitted to the CRU on Day -5.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTc increase from Baseline of &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF increase from Baseline of &gt;=60 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GIR in Part B in Placebo Group</title>
        <description>Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion.</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>GIR in Part B in Placebo Group</title>
          <description>Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion.</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GIR1 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.4" lower_limit="0" upper_limit="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178.3" lower_limit="176" upper_limit="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4" lower_limit="0" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196.5" lower_limit="181" upper_limit="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.7" lower_limit="92" upper_limit="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.7" lower_limit="103" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.7" lower_limit="143" upper_limit="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.4" lower_limit="68" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.9" lower_limit="411" upper_limit="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645.0" lower_limit="645" upper_limit="645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.4" lower_limit="217" upper_limit="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668.2" lower_limit="610" upper_limit="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="400.4" lower_limit="368" upper_limit="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.3" lower_limit="289" upper_limit="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338.0" lower_limit="338" upper_limit="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.3" lower_limit="322" upper_limit="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GIR in Part B in PF-05175157 200 mg BID Group</title>
        <description>Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion.</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>GIR in Part B in PF-05175157 200 mg BID Group</title>
          <description>Glucose Infusion Rate rates obtained averaging respectively the last 30 minutes of glucose infusion at steady state on Step 1 (ie 150 to 180 min) and Step 2 (ie 330 to 360 min) insulin infusion.</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GIR1 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.5" lower_limit="118" upper_limit="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.0" lower_limit="367" upper_limit="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334.2" lower_limit="311" upper_limit="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.3" lower_limit="277" upper_limit="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.9" lower_limit="160" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.2" lower_limit="68" upper_limit="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.7" lower_limit="113" upper_limit="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.2" lower_limit="201" upper_limit="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR1 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.9" lower_limit="159" upper_limit="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.2" lower_limit="270" upper_limit="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="896.5" lower_limit="871" upper_limit="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="896.3" lower_limit="864" upper_limit="1064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1078.5" lower_limit="1068" upper_limit="1079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="357.6" lower_limit="357" upper_limit="370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="564.0" lower_limit="520" upper_limit="656"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="693.1" lower_limit="666" upper_limit="728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="647.2" lower_limit="623" upper_limit="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="889.4" lower_limit="821" upper_limit="893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GIR2 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519.5" lower_limit="512" upper_limit="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EGP in Part B in Placebo Group</title>
        <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2)</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>EGP in Part B in Placebo Group</title>
          <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2)</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/kg fat free mass (FFM)/min</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGP0 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.540" lower_limit="1.49" upper_limit="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.690" lower_limit="1.64" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.285" lower_limit="1.24" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" lower_limit="1.55" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.965" lower_limit="1.89" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" lower_limit="1.50" upper_limit="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" lower_limit="1.47" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.518" lower_limit="1.49" upper_limit="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.600" lower_limit="0.57" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.585" lower_limit="0.55" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.525" lower_limit="0.49" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.500" lower_limit="0.49" upper_limit="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.808" lower_limit="0.75" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.830" lower_limit="0.82" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.560" lower_limit="0.55" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.825" lower_limit="0.78" upper_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.200" lower_limit="0.17" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.063" lower_limit="-0.09" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" lower_limit="-0.10" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.280" lower_limit="0.25" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.145" lower_limit="0.06" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.223" lower_limit="0.20" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" lower_limit="0.17" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.405" lower_limit="0.38" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EGP in Part B in PF-05175157 200 mg BID Group</title>
        <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2)</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>EGP in Part B in PF-05175157 200 mg BID Group</title>
          <description>EGP measured by means of euglycemic hyperinsulinemic clamp preceding insulin infusion (EGP0), on Step 1 insulin infusion (EGP1) and on Step 2 insulin infusion (EGP2)</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/kg fat free mass (FFM)/min</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGP0 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.240" lower_limit="1.23" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.445" lower_limit="1.42" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.083" lower_limit="2.03" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.708" lower_limit="1.68" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.695" lower_limit="1.67" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.615" lower_limit="1.59" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.690" lower_limit="1.64" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.393" lower_limit="1.25" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.448" lower_limit="1.43" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP0 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.345" lower_limit="1.33" upper_limit="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.568" lower_limit="0.54" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.22" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.788" lower_limit="0.69" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.575" lower_limit="0.54" upper_limit="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.183" lower_limit="1.12" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.538" lower_limit="0.52" upper_limit="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.765" lower_limit="0.74" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.555" lower_limit="0.53" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.193" lower_limit="0.11" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP1 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.418" lower_limit="0.35" upper_limit="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.253" lower_limit="0.23" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.165" lower_limit="0.09" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" lower_limit="-0.43" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.243" lower_limit="0.10" upper_limit="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.543" lower_limit="0.47" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.110" lower_limit="0.03" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" lower_limit="0.15" upper_limit="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.313" lower_limit="-0.42" upper_limit="-0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.253" lower_limit="-0.34" upper_limit="-0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGP2 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.198" lower_limit="0.19" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ra in Part B in Placebo Group</title>
        <description>Ra in fasting state and during insulin infusions (Step 1 and Step 2).</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Part B</title>
            <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ra in Part B in Placebo Group</title>
          <description>Ra in fasting state and during insulin infusions (Step 1 and Step 2).</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/kg BW/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Step 2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.245" lower_limit="4.18" upper_limit="4.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.325" lower_limit="6.26" upper_limit="6.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.793" lower_limit="2.72" upper_limit="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.835" lower_limit="6.56" upper_limit="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.400" lower_limit="3.97" upper_limit="5.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.940" lower_limit="3.86" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.553" lower_limit="4.37" upper_limit="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.225" lower_limit="4.16" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ra in Part B in PF-05175157 200 mg BID Group</title>
        <description>Ra in fasting state and during insulin infusions (Step 1 and Step 2).</description>
        <time_frame>6 weeks</time_frame>
        <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
        <group_list>
          <group group_id="O1">
            <title>PF-05175157 200 mg Twice a Day - Part B</title>
            <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ra in Part B in PF-05175157 200 mg BID Group</title>
          <description>Ra in fasting state and during insulin infusions (Step 1 and Step 2).</description>
          <population>Part B of the study was terminated due to the safety issue. Due to the limited participant number who completed study there no summary statistics were done by dosing regimen for Part B.</population>
          <units>mg/kg BW/min</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Step 2 Value 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.775" lower_limit="3.70" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.033" lower_limit="8.95" upper_limit="9.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.903" lower_limit="8.33" upper_limit="9.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.310" lower_limit="11.13" upper_limit="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.133" lower_limit="3.98" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.763" lower_limit="5.98" upper_limit="7.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.243" lower_limit="8.06" upper_limit="8.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.180" lower_limit="7.03" upper_limit="7.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.113" lower_limit="9.80" upper_limit="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step 2 Value 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.205" lower_limit="6.16" upper_limit="6.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to follow-up (up to approximately 3 days after the last clamp procedure in Part A and up to approximately 10 to 14 days after the last study drug administration in Part B)</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants in Part A</title>
          <description>Participants underwent 2 step euglycemic hyperinsulinemic clamp procedure and were infused with insulin according to a specified algorithm to reduce plasma glucose levels to approximately 100 milligram (mg)/deciliter (dL). In Step 1 of the clamp, each individual’s insulin infusion rate during the last 2 hours of the overnight infusion was increased by 10 mU/square meter (m^2)/minute (min). During Step 2, all participants received an insulin infusion, at a rate of 120 mU/m^2/min.</description>
        </group>
        <group group_id="E2">
          <title>PF-05175157 200 mg Twice a Day - Part B</title>
          <description>Participants received PF-05175157 200 mg twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo - Part B</title>
          <description>Participants received placebo twice a day at approximately 08:00 immediately before the morning meal, and at approximately 18:00 before the dinner meal. The treatment period was 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Part B of the study was terminated due to the safety issue. Due to the low number of participants who completed the study, there are no conclusions for PK or PD in Part B. The prioritization of Part A endpoints was done by inputs from team.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClnicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

